All In Biotech

Drug Trial Radar · NCT07323641

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

A Phase II Trial of Telisotuzumab Vedotin With Osimertinib for EGFR Mutated NSCLC With c-MET Overexpression That is Progressing on Osimertinib

Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 19, 2026

Primary completion

Feb 1, 2027

Study completion Feb 1, 2028

Sponsor

Lead sponsor
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AbbVie
First posted
Jan 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests how well telisotuzumab vedotin and osimertinib works for the treatment of non small cell lung cancer that is growing, spreading, or getting worse (progressive) and for which no treatment is currently available (incurable). Telisotuzumab vedotin is a monoclonal antibody, called telisotuzumab, linked to a toxic agent, called vedotin. Telisotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as c-Met receptors, and delivers vedotin to kill them. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving telisotuzumab vedotin and osimertinib may be effective for treating progressive, incurable non small cell lung cancer.

Conditions

  • Lung Non-Small Cell Carcinoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo tumor biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT scan

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • OsimertinibDrug

    Given PO

  • Survey AdministrationOther

    Ancillary studies

  • Telisotuzumab VedotinBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Up to 2 years
  2. Progression free survival (PFS)Time frame: From treatment initiation to disease progression per RECIST 1.1 criteria or death, up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.